| European Case Law Identifier: | ECLI:EP:BA:2017:T095013.20170203 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 03 February 2017 | ||||||||
| Case number: | T 0950/13 | ||||||||
| Application number: | 04758053.5 | ||||||||
| IPC class: | A61K 31/427 A61K 31/506 A61P 35/02 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | ||||||||
| Applicant name: | Bristol-Myers Squibb Holdings Ireland | ||||||||
| Opponent name: | APOTEX INC. | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request and auxiliary request 1: Sufficiency of disclosure - (no) Auxiliary request 2a: Sufficiency of disclosure - (yes), plausible technical concept Appeal decision - remittal to the department of first instance (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t130950eu1.html
Date retrieved: 17 May 2021